These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29868865)

  • 1. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.
    de Almeida TB; de Azevedo MCVM; Pinto JFDC; Ferry FRA; da Silva GAR; de Castro IJ; Baker P; Tanuri A; Haas DW; Cardoso CC
    J Antimicrob Chemother; 2018 Sep; 73(9):2460-2467. PubMed ID: 29868865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
    Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.
    Haas DW; Severe P; Jean Juste MA; Pape JW; Fitzgerald DW
    J Antimicrob Chemother; 2014 Aug; 69(8):2187-90. PubMed ID: 24695352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
    Haas DW; Bradford Y; Verma A; Verma SS; Eron JJ; Gulick RM; Riddler SA; Sax PE; Daar ES; Morse GD; Acosta EP; Ritchie MD
    Pharmacogenet Genomics; 2018 Jul; 28(7):179-187. PubMed ID: 29847509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.
    Decloedt EH; Sinxadi PZ; van Zyl GU; Wiesner L; Khoo S; Joska JA; Haas DW; Maartens G
    J Antimicrob Chemother; 2019 Mar; 74(3):699-709. PubMed ID: 30535366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
    Neary M; Lamorde M; Olagunju A; Darin KM; Merry C; Byakika-Kibwika P; Back DJ; Siccardi M; Owen A; Scarsi KK
    Clin Pharmacol Ther; 2017 Sep; 102(3):529-536. PubMed ID: 28187506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R
    Clin Pharmacokinet; 2016 Jul; 55(7):861-873. PubMed ID: 26715213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.
    Torgersen J; Bellamy SL; Ratshaa B; Han X; Mosepele M; Zuppa AF; Vujkovic M; Steenhoff AP; Bisson GP; Gross R
    Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):179-187. PubMed ID: 30168000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
    Powers V; Ward J; Gompels M
    HIV Med; 2009 Sep; 10(8):520-3. PubMed ID: 19486190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
    AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
    Sonenthal PD; Ratshaa B; Chimbengo G; Rantleru T; Ngoni T; Barenbaum S; Platoff R; Steenhoff AP; Gross R
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):773-7. PubMed ID: 24664872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
    Mollan KR; Tierney C; Hellwege JN; Eron JJ; Hudgens MG; Gulick RM; Haubrich R; Sax PE; Campbell TB; Daar ES; Robertson KR; Ventura D; Ma Q; Edwards DRV; Haas DW;
    J Infect Dis; 2017 Sep; 216(5):554-564. PubMed ID: 28931220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
    Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
    Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.